Elpiscience, a Shanghai immunoncology company, closed a $35 million Series B round led by Hillhouse Capital. Elpiscience has licensed technology from regional institutions and global partnerships to develop its pipeline, which now includes more than 10 molecules targeting novel pathways in cancer immunotherapy, including two assets that are ready for IND filing. In 2017, Elpiscience closed a $55 million Series A round that included Lilly Asia Ventures and CDH Investments.
Source: China Biotoday
